Aneuploid subtypes of circulating tumor cells and circulating tumor-derived endothelial cells predict the overall survival of advanced lung cancer

Objective This study aimed to detect circulating tumor cells (CTCs) and circulating tumor-derived endothelial cells (CTECs) in patients with advanced lung cancer, for describing the distribution characteristics of CTC and CTEC subtypes, exploring the correlation between CTC/CTEC subtypes and novel prognostic biomarkers. Methods A total of 52 patients with advanced lung cancer were enrolled in this study. Using the subtraction enrichment-immunofluorescence in situ hybridization (SE-iFISH) system, CTCs and CTECs derived from these patients were identified. Results Based on cell size, there were 49.3% small and 50.7% large CTCs, and 23.0% small and 77.0% large CTECs. Triploidy, tetraploidy, and multiploidy varied in the small and large CTCs/CTECs. Besides these three aneuploid subtypes, monoploidy was found in the small and large CTECs. Triploid and multiploid small CTCs and tetraploid large CTCs were associated with shorter overall survival (OS) in patients with advanced lung cancer. However, none of the CTECs subtypes showed a significant correlation with patient prognosis. In addition, we found strong positive correlations (P<0.0001) in the four groups including triploid small cell size CTCs and multiploid small cell size CTECs, and multiploid small cell size CTCs and monoploid small cell size CTECs. Furthermore, combined detection of the specific subtypes, including triploid small CTC and monoploid small CTEC, triploid small CTC and triploid small CTEC, and multiploid small CTC and monoploid small CTEC, were associated with poor prognosis in advanced lung cancer. Conclusions Aneuploid small CTCs are associated with the outcome of patients with advanced lung cancer. In particular, the combined detection of triploid small CTCs and monoploid small CTECs, triploid small CTCs and triploid small CTECs, and multiploid small CTCs and monoploid small CTECs has clinical significance for predicting prognosis in patients with advanced lung cancer.

[1]  Yong Song,et al.  A Multicenter Retrospective Study on the Prognosis of Stage III Unresectable Mutant Non-Small Cell Lung Cancer With Tyrosine Kinase Inhibitors Therapy , 2021, Frontiers in Oncology.

[2]  M. Yaspo,et al.  CD74 and CD44 Expression on CTCs in Cancer Patients with Brain Metastasis , 2021, International journal of molecular sciences.

[3]  L. Shen,et al.  Profiling heterogenous sizes of circulating tumor microemboli to track therapeutic resistance and prognosis in advanced gastric cancer , 2021, Human Cell.

[4]  Hong-yan Cheng,et al.  Combined detection and subclass characteristics analysis of CTCs and CTECs by SE-iFISH in ovarian cancer , 2021, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

[5]  J Zhang,et al.  Small Cell Size Circulating Aneuploid Cells as a Biomarker of Prognosis in Resectable Non-Small Cell Lung Cancer , 2021, Frontiers in Oncology.

[6]  J. Pinski,et al.  Baseline Circulating Tumor Cell Count as a Prognostic Marker of PSA Response and Disease Progression in Metastatic Castrate-Sensitive Prostate Cancer (SWOG S1216) , 2021, Clinical Cancer Research.

[7]  D. R. Lewis,et al.  Re: Annual Report to the Nation on the Status of Cancer, Part I: National Cancer Statistics. , 2020, The Journal of urology.

[8]  N. Sun,et al.  Combined detection of aneuploid circulating tumor‐derived endothelial cells and circulating tumor cells may improve diagnosis of early stage non‐small‐cell lung cancer , 2020, Clinical and translational medicine.

[9]  Katarzyna Wadowska,et al.  Title: Genetic Markers in Lung Cancer Diagnosis: A Review , 2020, International journal of molecular sciences.

[10]  P. Lin.  Aneuploid Circulating Tumor-Derived Endothelial Cell (CTEC): A Novel Versatile Player in Tumor Neovascularization and Cancer Metastasis , 2020, Cells.

[11]  A. Pircher,et al.  Systematic review: Soluble immunological biomarkers in advanced non-small-cell lung cancer (NSCLC). , 2020, Critical reviews in oncology/hematology.

[12]  A. Chaudhuri,et al.  Liquid Biopsies Using Circulating Tumor DNA in Non-Small Cell Lung Cancer. , 2020, Thoracic surgery clinics.

[13]  A. Sadewa,et al.  Serum MiRNA as Predictive and Prognosis Biomarker in Advanced Stage Non-small Cell Lung Cancer in Indonesia , 2020, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

[14]  Xiao-tian Dai,et al.  Urine cell‐free DNA as a promising biomarker for early detection of non‐small cell lung cancer , 2020, Journal of clinical laboratory analysis.

[15]  C. D. Dela Cruz,et al.  Lung Cancer 2020: Epidemiology, Etiology, and Prevention. , 2020, Clinics in chest medicine.

[16]  Jin-liang Wang,et al.  Tumor Mutation Burden as a Potential Biomarker for PD-1/PD-L1 Inhibition in Advanced Non-small Cell Lung Cancer , 2020, Targeted Oncology.

[17]  Lina Zhang,et al.  PD-L1+ aneuploid circulating tumor endothelial cells exhibit resistance to the checkpoint blockade immunotherapy in advanced NSCLC patients. , 2020, Cancer letters.

[18]  A. Jemal,et al.  Cancer statistics, 2020 , 2020, CA: a cancer journal for clinicians.

[19]  G. Ma,et al.  Dynamic monitoring of CD45-/CD31+/DAPI+ circulating endothelial cells aneuploid for chromosome 8 during neoadjuvant chemotherapy in locally advanced breast cancer , 2020, Therapeutic advances in medical oncology.

[20]  Baolan Li,et al.  Vimentin expression in circulating tumor cells (CTCs) associated with liver metastases predicts poor progression-free survival in patients with advanced lung cancer , 2019, Journal of Cancer Research and Clinical Oncology.

[21]  Swee Jin Tan,et al.  Addressing cellular heterogeneity in tumor and circulation for refined prognostication , 2019, Proceedings of the National Academy of Sciences.

[22]  Leonie L. Zeune,et al.  Single tube liquid biopsy for advanced non‐small cell lung cancer , 2019, International journal of cancer.

[23]  S. Lee,et al.  Technologies for circulating tumor cell separation from whole blood , 2019, Journal of Hematology & Oncology.

[24]  Q. Qian,et al.  Detecting and phenotyping of aneuploid circulating tumor cells in patients with various malignancies , 2018, Cancer biology & therapy.

[25]  Zhe Liu,et al.  Circulating tumor cells with karyotyping as a novel biomarker for diagnosis and treatment of nasopharyngeal carcinoma , 2018, BMC Cancer.

[26]  A. Ikhtiar,et al.  Circulating endothelial cells and microparticles as diagnostic and prognostic biomarkers in small-cell lung cancer. , 2018, Lung cancer.

[27]  H. Woodrow,et al.  : A Review of the , 2018 .

[28]  P. Lin.  Aneuploid CTC and CEC , 2018, Diagnostics.

[29]  K. Pantel,et al.  Prostate cancer: Circulating tumour cells in prostate cancer , 2018, Nature Reviews Urology.

[30]  Swee Jin Tan,et al.  An extracellular matrix-related prognostic and predictive indicator for early-stage non-small cell lung cancer , 2017, Nature Communications.

[31]  Chwee Teck Lim,et al.  An extracellular matrix-related prognostic and predictive indicator for early-stage non-small cell lung cancer , 2017, Nature Communications.

[32]  Caroline Dive,et al.  Progress and prospects of early detection in lung cancer , 2017, Open Biology.

[33]  B. Lim,et al.  Molecular characterization of circulating colorectal tumor cells defines genetic signatures for individualized cancer care , 2017, Oncotarget.

[34]  M. Hallman,et al.  Therapeutic management options for stage III non-small cell lung cancer , 2017, World journal of clinical oncology.

[35]  J. Crowley,et al.  The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[36]  Shuang Hou,et al.  Subclassification of prostate cancer circulating tumor cells by nuclear size reveals very small nuclear circulating tumor cells in patients with visceral metastases , 2015, Cancer.

[37]  Linda Li,et al.  Enhanced detection and comprehensive in situ phenotypic characterization of circulating and disseminated heteroploid epithelial and glioma tumor cells , 2015, Oncotarget.

[38]  L. Shen,et al.  Clinical significance of phenotyping and karyotyping of circulating tumor cells in patients with advanced gastric cancer , 2014, Oncotarget.

[39]  H. Inoue,et al.  Prognostic impact of the number of viable circulating cells with high telomerase activity in gastric cancer patients: a prospective study. , 2014, International journal of oncology.

[40]  J. Gomez-Codina,et al.  Prognostic significance of circulating tumor cells in advanced non-small cell lung cancer patients treated with docetaxel and gemcitabine , 2014, Clinical and Translational Oncology.

[41]  A. Goldkorn,et al.  Circulating Tumor Cells in Prostate Cancer , 2013, Cancers.

[42]  S. Sleijfer,et al.  Clinical value of circulating endothelial cell detection in oncology. , 2012, Drug discovery today.

[43]  K. Pantel,et al.  Plasticity of disseminating cancer cells in patients with epithelial malignancies , 2012, Cancer and Metastasis Reviews.

[44]  David Pellman,et al.  Causes and consequences of aneuploidy in cancer , 2012, Nature Reviews Genetics.

[45]  Caroline Dive,et al.  Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  C. Desimone,et al.  Ten-Year Relative Survival for Epithelial Ovarian Cancer , 2011, Obstetrics and gynecology.

[47]  Robert S. Kerbel,et al.  The multifaceted circulating endothelial cell in cancer: towards marker and target identification , 2006, Nature Reviews Cancer.

[48]  Geert J. P. L. Kops,et al.  On the road to cancer: aneuploidy and the mitotic checkpoint , 2005, Nature Reviews Cancer.

[49]  J. Xu,et al.  Quantified postsurgical small cell size CTCs and EpCAM+ circulating tumor stem cells with cytogenetic abnormalities in hepatocellular carcinoma patients determine cancer relapse. , 2018, Cancer letters.

[50]  R. Mehran,et al.  Molecular and Cellular Pathobiology Tumor Endothelial Markers De fi ne Novel Subsets of Cancer-Speci fi c Circulating Endothelial Cells Associated with Antitumor Ef fi cacy , 2014 .

[51]  J. Manson,et al.  Prospective Study of , 2007 .